Skip to main content
Erschienen in: Medical Oncology 2/2012

01.06.2012 | Original Paper

Eleven years of experience with AIDS-related lymphomas at the Institute of Oncology Ljubljana

verfasst von: Tanja Mesti, Tanja Južnič Šetina, Marjeta Vovk, Barbara Jezeršek Novaković

Erschienen in: Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Neoplastic diseases are currently recognized in more than 40% of HIV sero-positive patients, with AIDS-related lymphomas (ARL) being most common. A survey of the ARLs in patients attending our institute from 1998 to 2009 is given along with the clinical and pathological manifestations, treatment and outcomes. We conducted a retrospective chart review of patients treated for ARL between 1998 and 2009 at the Institute of Oncology Ljubljana. Patients were identified from the lymphoma database of our institute. Eight patients with ARL were diagnosed and treated at our Institute according to the then protocol for HIV sero-negative lymphoma patients. Seven patients received HAART. Six patients received prophylaxis for opportunistic infections and febrile neutropenia (FN), and 6 of them had at least one episode of FN. Seven patients are still alive and in complete remission 7–142 months after the diagnosis of ARL. One of the patients died of progressive lymphoma. The low incidence of ARL in the HIV-infected population, early stages at the presentation and the good response to treatment are not in accordance with the data from the literature. Whether this goes on account of the HAART treatment, prophylaxis for opportunistic infections and FN or a better follow-up of these patients remains to be answered. Also, the group is very small to make any definitive conclusions.
Literatur
2.
Zurück zum Zitat Slovenia. Annual report of HIV infection in Slovenia. Slovenia: Institute for Public Health Care; 2008. Slovenia. Annual report of HIV infection in Slovenia. Slovenia: Institute for Public Health Care; 2008.
3.
4.
Zurück zum Zitat Akanmu AS. AIDS associated maligancies. Afr J Med Sci. 2006;35(Suppl):57–70. Akanmu AS. AIDS associated maligancies. Afr J Med Sci. 2006;35(Suppl):57–70.
5.
Zurück zum Zitat Burgi A, et al. Incidence and risk factors for the occurrence of non AIDS defining cancers among human immunodefincency virus infected individuals. Cancer. 2005;104:1505–11.PubMedCrossRef Burgi A, et al. Incidence and risk factors for the occurrence of non AIDS defining cancers among human immunodefincency virus infected individuals. Cancer. 2005;104:1505–11.PubMedCrossRef
6.
Zurück zum Zitat Lim ST, Levine AM. Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. CA Cancer J Clin. 2005;55:229–41.PubMedCrossRef Lim ST, Levine AM. Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. CA Cancer J Clin. 2005;55:229–41.PubMedCrossRef
7.
Zurück zum Zitat Yarchoan R, Little RF. Immunosuppression related malignancies. In: DeVita, Hellman, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2008. p. 2401–17. Yarchoan R, Little RF. Immunosuppression related malignancies. In: DeVita, Hellman, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2008. p. 2401–17.
9.
Zurück zum Zitat Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003;4:22–9.PubMedCrossRef Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003;4:22–9.PubMedCrossRef
10.
Zurück zum Zitat Ometto L, et al. Molecular profile of Epstein-Barr virus in human immunodeficiency virus 1 type related lymphadenopathies and lymphomas. Blood. 1997;90:313–22.PubMed Ometto L, et al. Molecular profile of Epstein-Barr virus in human immunodeficiency virus 1 type related lymphadenopathies and lymphomas. Blood. 1997;90:313–22.PubMed
11.
Zurück zum Zitat Hecht LJ, Aster CJ. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21. Hecht LJ, Aster CJ. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21.
12.
Zurück zum Zitat Cote TR et al. for AIDS/Cancer Study Group. Non- Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer. 1997; 73:645–50. Cote TR et al. for AIDS/Cancer Study Group. Non- Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer. 1997; 73:645–50.
13.
Zurück zum Zitat Gabarre J, et al. Human immunodeficiency virus related lymphoma: relation between clinical features and histologic subtypes. Am J Med. 2001;111:704–11.PubMedCrossRef Gabarre J, et al. Human immunodeficiency virus related lymphoma: relation between clinical features and histologic subtypes. Am J Med. 2001;111:704–11.PubMedCrossRef
14.
Zurück zum Zitat Sandler AS, Kaplan LD. Diagnosis and management of systemic non Hodgkin’s lymphoma in HIV. Hematol Oncol Clin North Am. 1996;10:1111–24.PubMedCrossRef Sandler AS, Kaplan LD. Diagnosis and management of systemic non Hodgkin’s lymphoma in HIV. Hematol Oncol Clin North Am. 1996;10:1111–24.PubMedCrossRef
15.
Zurück zum Zitat Klatt EC, Nichols L, Noguchi TT. Evolving trends revealed by autopsies of patients with the acquired immunodeficiency syndrome. 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif, 1982–1993. Arch Pathol Lab Med. 1994;118:884–90.PubMed Klatt EC, Nichols L, Noguchi TT. Evolving trends revealed by autopsies of patients with the acquired immunodeficiency syndrome. 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif, 1982–1993. Arch Pathol Lab Med. 1994;118:884–90.PubMed
16.
17.
Zurück zum Zitat Straus DJ. Human immunodeficiency virus associated lymphomas. Med Clin North Am. 1997;81:495–510.PubMedCrossRef Straus DJ. Human immunodeficiency virus associated lymphomas. Med Clin North Am. 1997;81:495–510.PubMedCrossRef
18.
Zurück zum Zitat Tan B, Ratner L. The use of new antiretroviral therapy in combination with chemotherapy. Curr Opin Oncol. 1997;9:455–64.PubMedCrossRef Tan B, Ratner L. The use of new antiretroviral therapy in combination with chemotherapy. Curr Opin Oncol. 1997;9:455–64.PubMedCrossRef
19.
Zurück zum Zitat Weiss R. Acquired immunodeficiency syndrome related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer. 2006;106:1560–8.PubMedCrossRef Weiss R. Acquired immunodeficiency syndrome related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer. 2006;106:1560–8.PubMedCrossRef
20.
Zurück zum Zitat Hoffmann C. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003;17:1521–9.PubMedCrossRef Hoffmann C. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003;17:1521–9.PubMedCrossRef
22.
Zurück zum Zitat Ratner L, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171–8.PubMed Ratner L, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171–8.PubMed
23.
Zurück zum Zitat Gill PS, et al. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1987;107:502–5.PubMed Gill PS, et al. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1987;107:502–5.PubMed
24.
Zurück zum Zitat De Mario MD, Liebowitz DN. Lymphomas in the immunocompromised patient. Semin Oncol. 1998;25:492–502. De Mario MD, Liebowitz DN. Lymphomas in the immunocompromised patient. Semin Oncol. 1998;25:492–502.
25.
Zurück zum Zitat Tulpule A, et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res. 2002;26:121–7.PubMedCrossRef Tulpule A, et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res. 2002;26:121–7.PubMedCrossRef
26.
Zurück zum Zitat Lucia MB, et al. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J Acquir Immune Defic Syndr. 2002;30:369–78.PubMed Lucia MB, et al. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J Acquir Immune Defic Syndr. 2002;30:369–78.PubMed
27.
Zurück zum Zitat Levine AM, et al. Human immunodeficiency induced lymphoma. Prognostic factors predictive of survival. Cancer. 1991;68:2466–72.PubMedCrossRef Levine AM, et al. Human immunodeficiency induced lymphoma. Prognostic factors predictive of survival. Cancer. 1991;68:2466–72.PubMedCrossRef
28.
Zurück zum Zitat Kaplan LD, et al. Low dose compared with standard dose m-BACOD chemotherapy for non Hodgin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1641–8.PubMedCrossRef Kaplan LD, et al. Low dose compared with standard dose m-BACOD chemotherapy for non Hodgin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1641–8.PubMedCrossRef
29.
Zurück zum Zitat Kaplan LD, et al. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without Rituximab in patients with HIV-associated non Hodgkin lymphoma. AIDS malignancies consortium trial 010. Blood. 2005;106:1538–43.PubMedCrossRef Kaplan LD, et al. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without Rituximab in patients with HIV-associated non Hodgkin lymphoma. AIDS malignancies consortium trial 010. Blood. 2005;106:1538–43.PubMedCrossRef
30.
Zurück zum Zitat Boue F, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non Hodgkin lymphoma. J Clin Oncol. 2006;24:4123–8.PubMedCrossRef Boue F, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non Hodgkin lymphoma. J Clin Oncol. 2006;24:4123–8.PubMedCrossRef
31.
Zurück zum Zitat Spina M, et al. Rituximab and infusional cyclophosphamide, doxorubicin and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105:1891–7.PubMedCrossRef Spina M, et al. Rituximab and infusional cyclophosphamide, doxorubicin and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105:1891–7.PubMedCrossRef
32.
Zurück zum Zitat Sparano J, et al. Phase II Trial of infusional cyclophosphamide, doxorubicin and etoposide in patients with HIV-associated non Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group Trial (E 1494). J Clin Oncol. 2004;22:1491–500.PubMedCrossRef Sparano J, et al. Phase II Trial of infusional cyclophosphamide, doxorubicin and etoposide in patients with HIV-associated non Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group Trial (E 1494). J Clin Oncol. 2004;22:1491–500.PubMedCrossRef
33.
Zurück zum Zitat Sparano J for AIDS Malignancy Consortium. Trial 034: Randomized phase II trial of infusional EPOCH chemotherapy given either concurrently with or sequentially followed by rituximab in HIV-associated lymphoma. In: Paper presented at 10th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies: Bathesda, October 16–17, 2006. Abstract 11. Sparano J for AIDS Malignancy Consortium. Trial 034: Randomized phase II trial of infusional EPOCH chemotherapy given either concurrently with or sequentially followed by rituximab in HIV-associated lymphoma. In: Paper presented at 10th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies: Bathesda, October 16–17, 2006. Abstract 11.
34.
Zurück zum Zitat Little RF, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653–9.PubMedCrossRef Little RF, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653–9.PubMedCrossRef
36.
Zurück zum Zitat Ribera JM, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140:411–9.PubMedCrossRef Ribera JM, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140:411–9.PubMedCrossRef
37.
Zurück zum Zitat Rafaniello Raviele P, Pruner G, Maiorano E. Plasmablastic lymphoma: a review. Oral Dis. 2009;15:38–45.PubMedCrossRef Rafaniello Raviele P, Pruner G, Maiorano E. Plasmablastic lymphoma: a review. Oral Dis. 2009;15:38–45.PubMedCrossRef
38.
Zurück zum Zitat Harris E, Paneesha S, Jackson N, Jones L, Mahendra P. Burkitt’s lymphoma: single-centre experience with modified BFM protocol. Clin Lab Haematol. 2002;24:111–4.PubMedCrossRef Harris E, Paneesha S, Jackson N, Jones L, Mahendra P. Burkitt’s lymphoma: single-centre experience with modified BFM protocol. Clin Lab Haematol. 2002;24:111–4.PubMedCrossRef
Metadaten
Titel
Eleven years of experience with AIDS-related lymphomas at the Institute of Oncology Ljubljana
verfasst von
Tanja Mesti
Tanja Južnič Šetina
Marjeta Vovk
Barbara Jezeršek Novaković
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9951-7

Weitere Artikel der Ausgabe 2/2012

Medical Oncology 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.